CoChat

Reemergence of neural crest stem cell-like states in melanoma during disease progression and treatment

Open access
Diener, Johanna, Sommer, Lukas · 2021 · Stem Cells Translational Medicine

The DOI matches its Crossref record; 120 of the 122 references it cites were found in a registry or an index.

Abstract

Melanoma is the deadliest of all skin cancers due to its high metastatic potential. In recent years, advances in targeted therapy and immunotherapy have contributed to a remarkable progress in the treatment of metastatic disease. However, intrinsic or acquired resistance to such therapies remains a major obstacle in melanoma treatment. Melanoma disease progression, beginning from tumor initiation and growth to acquisition of invasive phenotypes and metastatic spread and acquisition of treatment resistance, has been associated with cellular dedifferentiation and the hijacking of gene regulatory networks reminiscent of the neural crest (NC)—the developmental structure which gives rise to melanocytes and hence melanoma. This review summarizes the experimental evidence for the involvement of NC stem cell (NCSC)-like cell states during melanoma progression and addresses novel approaches to combat the emergence of stemness characteristics that have shown to be linked with aggressive disease outcome and drug resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/sctm.20-0351

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Reacquisition of neural crest stem cell (NCSC)‐like characteristics in melanoma and its implications. Embryonic NCSCs (dark green) arise at the developing dorsal neural tube and migrate into the whole embryo to form different tissues such as craniofacial bone and cartilage, enteric and peripheral nervous system cells (light grey) and, amongst many others, also cells of the melanocyte lineage, specifically melanocyte stem cells (MeSCs), melanoblasts and melanocytes (brown). Due to malignant transformations, those cells can progress into melanoma. Different studies have shown that some melanoma cells (light green) can hijack embryonic NCSC programs, bestowing them with different advantageous characteristics. Melanoma cells with reacquired NCSC features have been associated with the ability to form novel tumors and sustain growth, increased cell invasiveness and metastasis formation, as well as the ability to resist different melanoma therapies and evade immune surveillance
FIGURE 1 Reacquisition of neural crest stem cell (NCSC)‐like characteristics in melanoma and its implications. Embryonic NCSCs (dark green) arise at the developing dorsal neural tube and migrate into the whole embryo to form different tissues such as craniofacial bone and cartilage, enteric and peripheral nervous system cells (light grey) and, amongst many others, also cells of the melanocyte lineage, specifically melanocyte stem cells (MeSCs), melanoblasts and melanocytes (brown). Due to malignant transformations, those cells can progress into melanoma. Different studies have shown that some melanoma cells (light green) can hijack embryonic NCSC programs, bestowing them with different advantageous characteristics. Melanoma cells with reacquired NCSC features have been associated with the ability to form novel tumors and sustain growth, increased cell invasiveness and metastasis formation, as well as the ability to resist different melanoma therapies and evade immune surveillanceCC BY-NC-ND · PubMed Central
FIGURE 2 Interfering with dedifferentiated, neural crest stem cell (NCSC)‐like melanoma cells to combat drug resistance. Different preclinical studies successfully managed to circumvent therapy resistance of melanoma cells or patient‐derived grafts in mice by targeting the reemergence of NCSC‐like melanoma states. Rambow et al 28 were able to attenuate the accumulation of NCSC‐like cells after BRAF/MEK inhibition by treating patient‐derived melanoma with an antagonist toward RXRG, a NCSC‐associated gene strongly upregulated within their drug resistant melanoma subpopulation. Similarly, Boshuizen et al 107 successfully targeted tumor growth by combining MAPK inhibition with a cytotoxic antibody against AXLhigh cells emerging as resistant cells after BRAF/MEK inhibition. AXL is associated with invasiveness and drug resistance in melanoma 60 but has also been associated with reemergence of NCSC states in melanoma. 106 Also, Tsoi et al 106 could show that MAPK inhibition as well as pro‐inflammatory signaling from immunotherapies promoted drug resistant, dedifferentiated melanoma cells, which were characterized by increased sensitivity to ferroptosis. The authors subsequently co‐treated melanoma cells with targeted therapy and the ferroptosis‐inducing drug Erastin, which led to decreased melanoma cell survival. Sáez‐Ayala et al 111 achieved to circumvent drug resistance by forced differentiation of melanoma cells due to treatment with methotrexate (MTX), which induced the expression of the melanocyte differentiation marker MITF and inhibited invasiveness. This drug was further combined with the cytotoxic prodrug TMECG, activated by tyrosinase (a target of MITF), which is expressed in differentiated melanocytes
FIGURE 2 Interfering with dedifferentiated, neural crest stem cell (NCSC)‐like melanoma cells to combat drug resistance. Different preclinical studies successfully managed to circumvent therapy resistance of melanoma cells or patient‐derived grafts in mice by targeting the reemergence of NCSC‐like melanoma states. Rambow et al 28 were able to attenuate the accumulation of NCSC‐like cells after BRAF/MEK inhibition by treating patient‐derived melanoma with an antagonist toward RXRG, a NCSC‐associated gene strongly upregulated within their drug resistant melanoma subpopulation. Similarly, Boshuizen et al 107 successfully targeted tumor growth by combining MAPK inhibition with a cytotoxic antibody against AXLhigh cells emerging as resistant cells after BRAF/MEK inhibition. AXL is associated with invasiveness and drug resistance in melanoma 60 but has also been associated with reemergence of NCSC states in melanoma. 106 Also, Tsoi et al 106 could show that MAPK inhibition as well as pro‐inflammatory signaling from immunotherapies promoted drug resistant, dedifferentiated melanoma cells, which were characterized by increased sensitivity to ferroptosis. The authors subsequently co‐treated melanoma cells with targeted therapy and the ferroptosis‐inducing drug Erastin, which led to decreased melanoma cell survival. Sáez‐Ayala et al 111 achieved to circumvent drug resistance by forced differentiation of melanoma cells due to treatment with methotrexate (MTX), which induced the expression of the melanocyte differentiation marker MITF and inhibited invasiveness. This drug was further combined with the cytotoxic prodrug TMECG, activated by tyrosinase (a target of MITF), which is expressed in differentiated melanocytesCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 73

Metadata

Authors
Diener, J., & Sommer, L.
Affiliations
University of Zurich (CH)
Corresponding author
Sommer, Lukas
Venue
Stem Cells Translational Medicine
Published
2020-12-01
Volume
10
Issue
4
Pages
522-533
ISSN
  • 2157-6564 (ISSN-L)
  • 2157-6580
OpenAlex
W3107037282
Cited by
64
References
122
Citations by year
2026: 4 · 2025: 11 · 2024: 10 · 2023: 12 · 2022: 19 · 2021: 7 · 2020: 1
FWCI
1.05
Type
journal article
Language
en
Open access
Locations
  • Stem Cells Translational Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc-nd)
  • Zurich Open Repository and Archive (University of Zurich)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
melanoma, neural crest stem cells, cancer stemness, dedifferentiation, treatment resistance, metastasis, gene regulatory networks, melanocyte development, targeted therapy resistance, immunotherapy resistance, disease progression
MeSH terms
Humans, Melanocytes, Melanoma, Neural Crest, Disease Progression, Drug Resistance, Neoplasm, Neural Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.